PrenaSeq NIPT solution
Comprehensive, decentralised, cost effective, LDT, NIPT workflow
The PrenaSeq NIPT solution is a non-invasive prenatal screening workflow aimed at enabling clinical laboratories to build validate a Laboratory Developed Test (LDT) solution in their laboratory and to run their own, decentralised and local NIPT service in an affordable and validated way.
Customers can choose elements of our workflow from pre-analytical products such as our Prenata Preserver tubes of cfDNA Bead Xtract (extraction kits), our cfDNA NGS library preparation reagents or the PrenaSeq software and there is an option to customise the workflow to suit their own labs needs or simply adopt the fully validated workflow and lean on us for advice on how to implement the method in your own laboratory.
Secure and scalable
Secure, cloud based analysis platform. Enables small to high throughput analysis in a secure, cost effective and rapid manner
Comprehensive analysis
Enables comprehensive chromosomal and sub-chromosomal analysis and resolution. Comprehensive aberration analysis and reporting including Trisomy 21,18,13, SCA, rare autosomal aneuploidies and microdeletion syndromes
Automation friendly workflow
Implement plasma plating, extraction, PCR-Free NGS library prep and library normalisation using standard lab automation and liquid handlers
Simple user interface with customisable reporting
Intuitive cloud based user interface enables customised reporting including selecting relevant reporting fields, saving reporting templates, review of results and QC to date and printing or saving of reports
Technical Performance
​​​
Comparison of PrenaSeq LDT at Clinical Lab
Clinical Laboratory (A) were running the Illumina VeriSeq V2 workflow and had been doing so for around 2 years. They Approached Prenata as they wished to build and validate their own workflow and had previously heard about our products from a colleague.
The laboratory ran a total of 266 samples previously run through the VeriSeq V2 workflow. Of these 266 samples they were significantly enriched for aneuploidy in order to test the PrenaSeq workflow they had implemented.
​
In total 54 out of the 266 samples were classed as positive by Illumina VeriSeq V2 and covering Trisomy's 21,18, 13, SCA, autosomal aneuploidies, CNV's and microdeletions of these PrenaSeq called all XXX aberrations.
​
​
Figure 1. Re-analysis and concordance evaluation for 266 samples previously processed across VeriSeq V2 within a european clinical laboratory
Request for product information or a quotation
Please let us have your details below so we can respond promptly to your interest. Thanks!